Cullinan Zipalertinib NDA Accepted for EGFR Ex20ins

The FDA accepted a New Drug Application for zipalertinib (CLN-081) for previously treated locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. The PDUFA target action date is February 27, 2027. The NDA, submitted by Cullinan Therapeutics (NASDAQ: CGEM) and partner Taiho Pharmaceutical, is supported by data from the Phase 2b REZILIENT1 trial.

CGEM closed at $17.43 on July 27, with a market cap under $1 billion. The stock is a micro-cap biotech with a single asset under FDA review.

What the Data Showed

REZILIENT1 met its primary endpoint of overall response rate. In the primary cohort of 125 patients who received prior platinum-based chemotherapy only, the confirmed ORR was 40% (95% CI, 31.3-49.1%). In 30 patients who had received prior amivantamab without another exon 20 TKI, ORR was 30%. In 21 patients who had both prior amivantamab and a prior exon 20 TKI, ORR dropped to 14%, suggesting cross-resistance.

The drug also showed intracranial activity: a 31.3% intracranial response rate by RANO-BM criteria, with a median intracranial duration of response of 8.1 months, including responses in leptomeningeal disease. CNS penetration matters in lung cancer, where brain metastases are common.

Zipalertinib is an oral, irreversible EGFR inhibitor designed to selectively target exon 20 insertion variants while sparing wild-type EGFR. The FDA granted Breakthrough Therapy designation in 2021. Toxicities were largely dermatologic.

Why This Matters

EGFR exon 20 insertion mutations account for roughly 1-2% of NSCLC cases, a difficult-to-treat subset where standard EGFR TKIs like osimertinib and erlotinib are ineffective because the mutations alter the drug-binding pocket. The competitive field thinned when Takeda voluntarily withdrew Exkivity (mobocertinib) in 2023 after a failed confirmatory trial, leaving J&J’s Rybrevant (amivantamab) as the primary option.

If approved, zipalertinib would be the first oral targeted therapy specifically designed for previously treated EGFR ex20ins NSCLC, filling the gap left by the Exkivity withdrawal. Rybrevant is a bispecific antibody administered intravenously. An oral alternative with a 40% response rate in chemo-pre-treated patients gives physicians and patients a more convenient option.

Cullinan’s partner Taiho discovered the drug using its proprietary Cysteinomix technology and is responsible for commercialization in certain territories. Cullinan holds US commercial rights. This is a pipeline-in-a-product story for a company trading near $17 with no revenue.

What to Watch

The February 27, 2027 PDUFA is the binary event. With Breakthrough Therapy designation and a 40% ORR in the primary cohort, the approval odds look reasonable, but the FDA has tightened standards on single-arm Phase 2b approvals since the Exkivity withdrawal. The 14% ORR in the heavily pre-treated subgroup with prior amivantamab and TKI exposure is a weakness the FDA may scrutinize.

For context on EGFR-targeted lung cancer approvals, GSK’s recent Jideytro approval in ROS1 lung cancer illustrates how the FDA is handling targeted oncology drugs in niche NSCLC populations. The broader lesson: a PDUFA date on a single-arm Phase 2b dataset is a higher-risk regulatory proposition than one backed by a registrational Phase 3. Cullinan investors have six months to weigh whether 40% ORR is enough.

Source: Cullinan/Taiho NDA acceptance press release | REZILIENT1 on ClinicalTrials.gov